Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
| Заболевание | Major Depressive Disorder, Depression |
|---|---|
| Фаза | Фаза 3 |
| Спонсор | Levomecor Inc. |
| Статус | Прекращено |
| Участники | 27 участн. |
| Вмешательство | REL-1017 |
| Дата начала | 17.08.2023 |
| Дата завершения | 19.12.2024 |
| Публикация результатов | 10.07.2026 |
Кратко
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
| REL-1017 | -16.8 ± 7.62 Scores on a scale (MADRS10) |
|---|---|
| Placebo | -13.4 ± 9.55 Scores on a scale (MADRS10) |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital